Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05143970
Title A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Institut Paoli-Calmettes
Indications

pancreatic carcinoma

Advanced Solid Tumor

stomach carcinoma

lung carcinoma

ovarian carcinoma

esophageal carcinoma

breast carcinoma

gastroesophageal adenocarcinoma

endometrial carcinoma

Therapies

IPH5301

IPH5301 + Paclitaxel + Trastuzumab

Age Groups: adult | senior
Covered Countries FRA


No variant requirements are available.